Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 6/2010

01-06-2010 | Special Article

An oral history of MASCC, its origin and development from MASCC's beginnings to 2009

Authors: Cynthia N. Rittenberg, Judith L. Johnson, Gerald M. Kuncio

Published in: Supportive Care in Cancer | Issue 6/2010

Login to get access

Abstract

Introduction

This paper presents an oral history from the mid-1980s to 2009 of the start and evolution of the Multinational Association of Supportive Care in Cancer (MASCC) as seen through the recollections of the founders and early leaders. The growth of the supportive cancer care movement and MASCC’s contribution to oncology supportive care is described.

Discussion

As science was making progress towards better cancer treatment, a group of professionals began to research ways to prevent or mitigate the symptoms and side effects that accompany the disease and its treatments. Joining forces, they created an international, multidisciplinary organization to address and promulgate evidence-based practices of cancer supportive care. Through annual international scientific symposia, a peer-reviewed journal, an accessible website, and study group projects such as guidelines and tools, MASCC is accomplishing its mission.
Appendix
Available only for authorised users
Literature
1.
Senn HJ (1993) How “supportive” is yet another international oncology journal? Support Care Cancer 1(1):1CrossRef
2.
3.
Senn HJ, Glaus A (1987) Supportive care in cancer recent results in cancer research. Springer, Heidelberg
4.
Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051PubMed
5.
Ballatori E, Roila F, De Angelis V, Ciccarese G, Palladino MA, Tonato M, Del Favero A, Herrstedt J, Dicato M, Du Bois A, Hesketh P, Kris M, Gralla RJ (1997) Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Support Care Cancer 5:269–273CrossRefPubMed
6.
Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811–819CrossRef
7.
8.
9.
Gralla RJ, Roila F, Tonato M (2005) The 2004 Perugia antiemetic consensus guideline process: methods, procedures and participants. Support Care Cancer 13(2):77–79CrossRefPubMed
10.
Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, duBois A, Tonato M (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an update. Support Care Cancer 13(2):80–84CrossRefPubMed
11.
Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13(2):85–96CrossRefPubMed
12.
Herrstedt J, Koeller JM, Roila F, Hesketh PJ, Warr D, Rittenberg C, Dicato M (2005) Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 13(2):97–103CrossRefPubMed
13.
Roila F, Warr D, Clark-Snow RA, Tonato M, Gralla RJ, Einhorn LH, Herrstedt J (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13(2):104–108CrossRefPubMed
14.
Tonato M, Clark-Snow RA, Osoba D, Del Favero A, Ballatori E, Borjeson S (2005) Emesis induced by low or minimal emetic risk chemotherapy. Support Care Cancer 13(2):109–111CrossRefPubMed
15.
Einhorn LH, Rapoport B, Koeller J, Grunberg SM, Feyer P, Rittenberg C, Aapro M (2005) Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 13(2):112–116CrossRefPubMed
16.
Aapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13(2):117–121CrossRefPubMed
17.
Feyer P, Maranzano E, Molassiotis A, Clark-Snow RA, Roila F, Warr D, Olver I (2005) Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer 13(2):122–128CrossRefPubMed
18.
Roila F, Feyer P, Maranzano E, Olver I, Clark-Snow RA, Warr D, Molassiotis A (2005) Antiemetics in children receiving chemotherapy. Support Care Cancer 13(2):129–131CrossRefPubMed
19.
Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool. J Pain Symptom Manage 34(2):148–159CrossRefPubMed
20.
Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST, for the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046CrossRefPubMed
21.
Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE, for the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831CrossRefPubMed
22.
Kav S, Bostanci H (2005) Nurses attendance of patient education and follow-up for oral chemotherapy treatment in Turkey. Support Care Cancer 13(6):45
23.
Kav S, Johnson J, Rittenberg C, Fernandez-Ortega P, Suominen T, Olsen PR, Patiraki E, Porock D, Dahler A, Toliusiene J, Tadic D, Pittayapan P, Roy V, Wang Q, Colak M, Saca-Hazboun H, Makumi D, Dadmon I, Ben Ami S, Anderson E, Clark-Snow R (2008) Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment: an international survey. Support Care Cancer 16(9):1075–1083CrossRefPubMed
24.
Kav S, Schulmeister L, Nirenberg A, Barber L, Johnson J, Rittenberg C (2009) Development of the MASCC teaching tool for patients receiving oral agents for cancer. Support Care Cancer. doi:10.​1007/​s00520-009-0692-5
25.
Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18(4):509–522
26.
Metadata
Title
An oral history of MASCC, its origin and development from MASCC's beginnings to 2009
Authors
Cynthia N. Rittenberg
Judith L. Johnson
Gerald M. Kuncio
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 6/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0830-0

Other articles of this Issue 6/2010

Supportive Care in Cancer 6/2010 Go to the issue

Original Article

Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study

Original Article

Nutritional support for head and neck cancer patients receiving radiotherapy: a systematic review

Original Article

Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function

Original Article

Immediate facial rehabilitation in cancer patients using CAD–CAM and rapid prototyping technology: a pilot study

Original Article

Evaluation of analgesic effect and safety of fentanyl transdermal patch for cancer pain as the first line

Letter to the Editor

Letter to the editor
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits